A Preview on Global Lung Cancer Therapeutics Market

Lung Cancer – A Brief Outline

Lung cancer is also known as lung carcinoma is a medical condition where there occurs uncontrolled growth of abnormal cells that starts in one or both of the lungs usually in the cells that line the air passages. These abnormal cells divide rapidly and form tumors that undermine the lung’s ability to provide to the bloodstream with oxygen. The tumors that remain in one place and do not appear to spread are known as ‘benign tumors’ and those that spread to other parts of the body are known as ‘malignant tumors’ that are more dangerous.

According to World Health Organization (WHO), more than seven million deaths globally occur each year are caused by lung cancer representing about 13% of the all global deaths. In the United States of America, there had occurred about 158, 040 lung cancer deaths by the end of 2015 and as such, makes up to 14% of all newly diagnosed cancers. The causes of lung cancer include smoking (90% of cases), inherited genetic mutations, family history of lung cancer, exposure to radon etc. Lung cancer can be broadly classified into two main types – one is Non-Small Cell Lung Cancer (NSCLC) that accounts for 80% of lung cancers and the other one is small cell lung cancer that accounts for the remaining 20%.

Lung Cancer Therapeutics Market – Global Industry Analysis

The lung cancer treatment options are usually through chemotherapy, radiotherapy, surgery etc even though, with the launch of targeted therapies for advanced stage NCLC patients through drugs such as Iressa (gefitinib), Tarceva (erlotinib), and Xalkori (crizotinib) has shifted the treatment procedures towards personalized medicine leading  to the exponential growth of the lung cancer therapeutics market size. The global lung cancer therapeutics market worth was US$5.65 billion in 2016 that is estimated to grow at a CAGR of 6.7% to reach US$7.81 billion by the end of 2021. The adoption of lung cancer drugs and innovative lung surgeries are expected to heighten the growth parameters of the lung cancer therapeutics market.

Download free sample report:http://www.marketdataforecast.com/market-reports/global-lung-cancer-therapeutics-market-893/request-sample

 Factors such as huge demand from rising diagnostic centers across the globe, investment, and grants from governments and private players are driving the market. The successful trials and FDA approvals (in the United States of America) are the key factors that are creating a huge scope of global lung cancer therapeutics market.  The growth of lung cancer therapeutics market as per the global lung cancer therapeutics market forecast is expected to be dominated by drugs such as ta lactoferrin (Agennix), Xalkori (Pfizer) and by ARQ 197 (ArQule/Daiichi Sankyo) by the end of 2020. According to World Health Organization (WHO), lung cancer prevalence is expected to be rampant in the emerging markets such as the BRIC (Brazil, Russia, India and China) and other Asian and African markets due to an increase use of tobacco products, which is the primary cause of 90% of all lung cancers.

It is expected that the factors such as the launch of premium priced immuno-oncology (I/O) and targeted pipeline agents will drive the uptake of new therapies will help in the expansion of the global lung cancer therapeutics industry.  Developing economies such as India, Sri Lanka, and Vietnam are making huge investments in the improved healthcare systems and healthcare spending leading to a huge market potential for the global lung cancer therapeutic market.

Segmentation of global lung cancer therapeutic market – Summary

The global lung cancer therapeutic market is segmented or divided based on Treatment Type, Drug Type, Geography and further divided under each of these heads as shown in the tabular format shown herein below-


Treatment Type Drug Type Geography






North America

Radiotherapy – External beam, Internal beam, Systemic


Taxol Latin America


Camptosar Europe




Middle East









Table: 1 – Market Segmentation of Global Lung Cancer Therapeutic Market


Under the treatment type segmentation – Radiotherapy accounts for the largest lung cancer therapeutics market share due to accessibility and availability of radiotherapy centers across hospitals globally. Based on the geographical segment, North America and Europe leads the group with the United States of America emerging as the key player in this segment.

Inquire before buying:http://www.marketdataforecast.com/market-reports/global-lung-cancer-therapeutics-market-893/inquire

Asia-Pacific regions such as India, China, and Sri Lanka are emerging as the developing regions for the global lung cancer therapeutics market due to the high occurrence of lung diseases along with rising pollution levels. The major key players or companies involved in lung cancer therapeutics include – Astellas Pharma, AstraZeneca Plc, Hoffman-LaRoche, Pfizer Inc, and GlaxoSmithKline, Eli Lilly and Company etc. In the coming decades, the launch of new generation EGFR, ALK TKIs, and BRAF inhibitors will significantly promote the sales of targeted therapies, especially in NSCLC segment.

Visit here for more reports: http://www.marketdataforecast.com/

Share this post:

Related Posts

Leave a Comment